Processa Pharmaceuticals (PCSA) Change in Account Payables (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Change in Account Payables came in at -$216426.0 in Q1 2026, up 34.08% YoY from -$161414.6 in Q1 2025, and down 165.66% on a QoQ basis from $329624.0 in Q4 2025.
Processa Pharmaceuticals (PCSA) Change in Account Payables (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Change in Account Payables data on file, last reported at -$216426.0 in Q1 2026.
- Quarterly Change in Account Payables rose 34.08% year-over-year to -$216426.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $287810.0 (up 196.13% YoY) and the FY2025 annual result came in at $175916.0, down 69.1% from the prior year.
- Change in Account Payables declined to -$216426.0 in Q1 2026, from $329624.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $497718.0 in Q2 2024 to a low of -$328320.0 in Q1 2025.
- A 5-year average of $31943.8 and a median of $5419.5 in 2022 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables plunged 68103.92% — and 2024, when it soared 4513.63%.
- Tracing PCSA's Change in Account Payables over 5 years: stood at $51.0 in 2022, then sank by 68103.92% to -$34682.0 in 2023, then surged by 587.77% to $169170.0 in 2024, then soared by 94.85% to $329624.0 in 2025, then tumbled by 165.66% to -$216426.0 in 2026.
- The last three Change in Account Payables figures came in at -$216426.0 (Q1 2026), $329624.0 (Q4 2025), and -$58582.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | 819,068.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -216,426.00 |
| Mar 31, 2026 | -216,426.00 |
| Dec 31, 2025 | 329,624.00 |
| Dec 31, 2025 | 329,624.00 |
| Sep 30, 2025 | -58,582.00 |
| Sep 30, 2025 | -58,582.00 |
| Jun 30, 2025 | 233,194.00 |
| Jun 30, 2025 | 233,194.00 |
| Mar 31, 2025 | -328,320.00 |
| Mar 31, 2025 | -328,320.00 |
| Dec 31, 2024 | 169,170.00 |
| Dec 31, 2024 | 169,170.00 |
| Sep 30, 2024 | -241,376.00 |
| Sep 30, 2024 | -241,376.00 |
| Jun 30, 2024 | 497,718.00 |
| Jun 30, 2024 | 497,718.00 |
| Mar 31, 2024 | 143,751.00 |
| Mar 31, 2024 | 143,751.00 |
| Dec 31, 2023 | -34,682.00 |
| Dec 31, 2023 | -34,682.00 |